Anti-Inflammatory Effects of Clarstatin, a Shared-Epitope-Antagonistic Cyclic Peptide, on Experimental Autoimmune Uveitis in Mice.
Clarstatin showed a significant reduction in inflammation in mouse models of autoimmune uveitis, but its clinical relevance in humans remains to be established.
Where it sits
this study against the rest of the ara 290 corpusSummary and findings
This study evaluated the effects of Clarstatin, a cyclic peptide, on experimental autoimmune uveitis (EAU) in mouse models. The peptide was administered intraperitoneally, and its impact on clinical and histological scores was compared to that of corticosteroids. Results indicated a significant reduction in inflammation markers and clinical scores.
Abstract
<h4>Purpose</h4>Polymorphism and mutations of human leukocyte antigens (HLAs) and calreticulin are risk factors for uveitis. Here, we sought to determine the therapeutic effects of Clarstatin, a cyclic peptide antagonist of the HLA shared-epitope-calreticulin interaction, in experimental autoimmune uveitis (EAU) models.<h4>Methods</h4>Mice were injected with Clarstatin intraperitoneally and its effect was compared to that of corticosteroid. EAU was evaluated clinically and histologically. Ocular infiltration of CD45+ hematopoietic cells and splenocyte CD4+ expression were determined using immunofluorescence and flow cytometry (fluorescence-activated cell sorting [FACS]). ELISA was used to measure the ocular level of the proinflammatory cytokines.<h4>Results</h4>Clarstatin significantly ameliorated the severity of EAU in the C57BL/6J mild and the B10.RIII severe mice models. There was a significant dose and time-dependent decrease, in the range of 30% to 80%, in the clinical score (P < 0.05), histological score (P < 0.05), and number of retinal and spleen CD45+ cells (P < 0.05 and P < 0.001, respectively), a comparable effect to corticosteroid. Clarstatin reduced the intraocular levels of interleukin 6 (IL-6; P < 0.05) and monocyte chemoattractant protein-1 (MCP-1; P < 0.01) by 41% and 59%, respectively.<h4>Conclusions</h4>Systemic delivery of Clarstatin significantly improved mild and severe EAU. Its potential anti-inflammatory therapeutic effects represent a novel mode of treatment in ocular inflammation. It may also be a relevant treatment modality in systemic autoimmune conditions in which calreticulin plays a role in their pathogenesis.
Background
The study addresses the inflammatory processes involved in autoimmune uveitis, a condition that can lead to vision loss. Previous research has indicated that targeting specific epitopes may mitigate inflammatory responses. This study is significant as it explores a novel cyclic peptide, Clarstatin, for its potential anti-inflammatory properties in a mouse model.
Methods
The study utilized a mouse model of experimental autoimmune uveitis to evaluate the effects of Clarstatin. Specifics regarding the sample size, dosing regimen, and duration of treatment were not reported in the abstract. Primary and secondary outcome measures related to inflammation were assessed, but details were not provided.
Results
Not reported in abstract.
Interpretation
The findings, while potentially interesting, lack detailed reporting of effect sizes and statistical significance. Without clear numeric outcomes, it is challenging to determine the clinical relevance of the results. Additionally, the use of a rodent model raises questions about the applicability of these findings to human conditions.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.